9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management
Key Takeaways
Gestational diabetes mellitus (GDM) is driven by placental secretion of human placental lactogen (hPL), progesterone, growth hormone, and cortisol, which cause marked peripheral insulin resistance that peaks during the late second and early third trimesters.
Diagnostic screening occurs universally at 24 to 28 weeks gestation (or early in high-risk women) via either the Two-Step ACOG method (50-g non-fasting GCT followed by 100-g 3-hr fasting OGTT, requiring >=2 abnormal values) or the One-Step IADPSG method (75-g 2-hr fasting OGTT, requiring >=1 abnormal value).
Strict pregnancy glycemic targets are: fasting blood glucose <95 mg/dL, 1-hour postprandial <140 mg/dL, and 2-hour postprandial <120 mg/dL.
Medical Nutrition Therapy (MNT; 33–40% complex carbohydrates, 20% protein, 40% healthy fats) and physical activity are first-line; insulin is the gold-standard pharmacotherapy when MNT fails to achieve targets within 1 to 2 weeks, as it does not cross the placenta.
Diet-controlled GDM (A1GDM) may undergo expectant management to 40 6/7 weeks, whereas medication-controlled GDM (A2GDM) requires antenatal surveillance starting at 32–36 weeks and delivery between 39 0/7 and 39 6/7 weeks, followed by a 75-g 2-hr OGTT at 4 to 12 weeks postpartum.
Pathophysiology of Gestational Insulin Resistance
Pregnancy is a naturally diabetogenic state characterized by progressive, physiological insulin resistance. This adaptation ensures that maternal glucose is preferentially shunted across the placenta via facilitated diffusion (GLUT-1 transporters) to sustain rapid embryonic and fetal development.
Placental Diabetogenic Hormones
Beginning around 20 to 24 weeks gestation and peaking in the third trimester, the syncytiotrophoblast secretes an array of counter-regulatory hormones:
- Human Placental Lactogen (hPL / Human Chorionic Somatomammotropin): The primary mediator of maternal insulin resistance. hPL stimulates lipolysis, releasing maternal free fatty acids for maternal energy while impairing post-receptor insulin signaling in maternal skeletal muscle and adipose tissue.
- Progesterone & Estrogen: Inhibit glucose uptake in peripheral tissues and downregulate insulin receptor substrate-1 (IRS-1).
- Placental Growth Hormone (PGH): Modifies maternal hepatic gluconeogenesis and somatomedin generation.
- Cortisol & Prolactin: Elevated maternal free cortisol further promotes gluconeogenesis and blunts peripheral insulin sensitivity.
- Tumor Necrosis Factor-alpha (TNF-α): Placental cytokine that strongly impairs insulin receptor autophosphorylation.
In healthy pregnancies, maternal pancreatic beta cells undergo compensatory hyperplasia and hypertrophy, increasing insulin secretion by 200% to 250% to maintain maternal euglycemia. Gestational diabetes mellitus (GDM) develops when pancreatic reserve is inadequate to overcome this physiological peripheral insulin resistance.
Screening & Diagnostic Paradigms: Two-Step vs. One-Step
Screening Strategy & Timing
- Universal Screening: Conducted between 24 0/7 and 28 6/7 weeks gestation for all pregnant women not previously identified with diabetes.
- Early Screening: Conducted at the initial prenatal visit in women with major risk factors: pre-pregnancy BMI ≥25 kg/m² (≥23 kg/m² in Asian Americans) plus high-risk markers (prior GDM, HbA1c ≥5.7%, polycystic ovary syndrome, first-degree relative with type 2 diabetes, or prior macrosomic infant ≥4,000 g). If early testing is negative, repeat screening at 24 to 28 weeks remains mandatory.
The Two-Step Approach (ACOG & Carpenter-Coustan Criteria)
Standard in the United States:
- Step 1: 50-g Glucose Challenge Test (GCT): Non-fasting screening test. A 50-gram oral glucose load is consumed, and venous plasma glucose is measured 1 hour later.
- Threshold: A plasma glucose of ≥130 or ≥140 mg/dL (institutional standard) is considered abnormal and mandates proceeding to Step 2.
- Direct Diagnosis: If the initial 50-g screen is ≥200 mg/dL, GDM is diagnosed directly without requiring the 3-hour test.
- Step 2: 100-g 3-Hour Oral Glucose Tolerance Test (OGTT): Performed in the morning after an overnight fast of 8 to 14 hours following at least 3 days of unrestricted carbohydrate intake (>150 g/day).
| Measurement Time | Carpenter-Coustan Threshold (mg/dL) | NDDG Threshold (mg/dL) |
|---|---|---|
| Fasting | ≥95 | ≥105 |
| 1-Hour | ≥180 | ≥190 |
| 2-Hour | ≥155 | ≥165 |
| 3-Hour | ≥140 | ≥145 |
Note
Under the Carpenter-Coustan criteria, at least two of the four plasma glucose values must meet or exceed the threshold to confirm a diagnosis of GDM. If only one value is elevated, the patient is at increased risk for macrosomia and is often monitored or re-evaluated at 32 weeks.
The One-Step Approach (IADPSG / ADA Criteria)
Endorsed internationally by the International Association of Diabetes and Pregnancy Study Groups (IADPSG) and World Health Organization (WHO):
- Patient undergoes a 75-g 2-hour fasting OGTT at 24 to 28 weeks.
- Diagnostic thresholds: Fasting ≥92 mg/dL, 1-hour ≥180 mg/dL, 2-hour ≥153 mg/dL.
- Diagnosis is confirmed if any single value meets or exceeds these cutoffs.
Glycemic Targets & Medical Nutrition Therapy
Glycemic Targets in Pregnancy
Maintaining strict maternal euglycemia prevents fetal hyperinsulinemia, macrosomia, neonatal hypoglycemia, and shoulder dystocia:
- Fasting Blood Glucose: <95 mg/dL (5.3 mmol/L).
- 1-Hour Postprandial: <140 mg/dL (7.8 mmol/L).
- 2-Hour Postprandial: <120 mg/dL (6.7 mmol/L).
- Hemoglobin A1c: Target in pregnancy is <6.0% (42 mmol/mol), provided it can be achieved without significant maternal hypoglycemia. A1c turnover is accelerated in pregnancy due to increased red cell production.
Medical Nutrition Therapy (MNT)
First-line therapy for all patients diagnosed with GDM (A1GDM). An individualized nutritional plan developed with a registered dietitian:
- Caloric Intake: 30 kcal/kg/day for normal-weight women; 22 to 25 kcal/kg/day for overweight/obese women (avoiding caloric restriction <1,600–1,800 kcal/day to prevent starvation ketosis).
- Macronutrient Distribution:
- Complex Carbohydrates: 33% to 40% of total daily calories, distributed across meals. Emphasize low glycemic index foods rich in fiber.
- Protein: 20% of daily calories.
- Fat: 40% of daily calories, emphasizing monounsaturated and polyunsaturated fats.
- Meal Patterning: Three small-to-moderate meals and 2 to 3 snacks daily. A bedtime snack containing complex carbohydrates and protein is mandatory to prevent nocturnal hepatic glycogen depletion, overnight hypoglycemia, and morning rebound ketonemia.
- Physical Activity: Moderate aerobic exercise for 30 minutes, 5 days per week, or 10 to 15 minutes of brisk walking following each meal blunts postprandial glucose excursions.
Pharmacotherapy, Fetal Surveillance & Delivery
Pharmacologic Management
When MNT and exercise fail to achieve target blood glucose levels within 1 to 2 weeks, pharmacologic therapy is indicated (A2GDM).
- Insulin (First-Line Gold Standard): Does not cross the placenta and achieves predictable glycemic control without fetal exposure.
- Regimens: Split-dose basal-bolus therapy utilizing intermediate-acting NPH insulin (basal) and rapid-acting analogs insulin lispro or aspart (bolus before meals). Rapid-acting analogs exhibit minimal transplacental transfer and have favorable safety profiles.
- Starting Dose: Total daily dose calculated at 0.7 to 1.0 unit/kg actual pregnancy weight, titrated according to patient logs.
- Oral Antihyperglycemic Agents (Second-Line / Limitations):
- Metformin: Crosses the placenta readily, producing umbilical cord concentrations equal to or higher than maternal blood. While not teratogenic, it has high failure rates (up to 30–50% require supplemental insulin) and may alter long-term offspring metabolic programming. Reserved for patients who refuse or cannot afford/administer insulin.
- Glyburide: Crosses the placenta and is associated with significantly higher rates of neonatal hypoglycemia and macrosomia compared to insulin. It is not recommended as first-line therapy.
Important
Insulin remains the only first-line pharmacotherapy recommended by ACOG and the ADA for gestational diabetes because oral agents cross the placenta and lack reassuring long-term offspring outcome data.
Antenatal Fetal Surveillance & Delivery Timing
- Diet-Controlled GDM (A1GDM): Fetal surveillance (NST/BPP) is generally not required before 40 weeks unless comorbidities arise. Expectant management is permitted up to 40 6/7 weeks gestation.
- Medication-Controlled GDM (A2GDM): Initiate weekly or twice-weekly antenatal surveillance (non-stress testing [NST] and/or biophysical profile [BPP]) starting at 32 to 36 weeks gestation. Scheduled delivery is recommended between 39 0/7 and 39 6/7 weeks gestation.
- Macrosomia & Cesarean Consideration: If ultrasound estimated fetal weight (EFW) exceeds 4,500 grams, clinicians should counsel patients regarding the option of scheduled cesarean delivery to avoid traumatic shoulder dystocia and brachial plexus injury.
Postpartum Metabolic Re-evaluation
Because placental expulsion removes the source of anti-insulin hormones, insulin resistance drops precipitously immediately postpartum. Discontinue all insulin and oral agents following delivery.
- Screening Interval: Perform a 75-g 2-hour fasting OGTT at 4 to 12 weeks postpartum to screen for persistent diabetes or prediabetes.
- Interpretation (Non-pregnant criteria): Fasting <100 mg/dL and 2-hr <140 mg/dL is normal; fasting 100–125 mg/dL indicates impaired fasting glucose; 2-hr 140–199 mg/dL indicates impaired glucose tolerance; fasting ≥126 mg/dL or 2-hr ≥200 mg/dL confirms type 2 diabetes mellitus.
- Long-Term Risk: Women with prior GDM have a 50% to 70% lifetime risk of developing overt type 2 diabetes and require re-screening every 1 to 3 years.
A 28-year-old primigravida at 26 weeks gestation undergoes routine gestational diabetes screening. Her non-fasting 50-g 1-hour glucose challenge test (GCT) result is 156 mg/dL. She has no personal or family history of diabetes, and her vital signs and routine physical examination are normal. What is the most appropriate next step in clinical management?
Diagnose gestational diabetes mellitus immediately and initiate medical nutrition therapy.
Reassure the patient that her blood sugar is normal and repeat the 50-g challenge at 32 weeks.
Order a diagnostic 100-g 3-hour oral glucose tolerance test (OGTT) following an overnight fast.
Initiate basal NPH insulin therapy and schedule twice-weekly non-stress testing.
A 32-year-old G2P1 at 29 weeks gestation was diagnosed with gestational diabetes mellitus 2 weeks ago. She has diligently followed an individualized medical nutrition therapy (MNT) plan and performed moderate physical activity. Her self-monitoring blood glucose log over the past 14 days reveals fasting levels consistently between 102 and 114 mg/dL, with 1-hour postprandial readings ranging between 144 and 158 mg/dL. What is the most appropriate next step in clinical management?
Initiate insulin therapy as the preferred first-line pharmacologic agent to achieve target glycemic goals.
Prescribe oral glyburide 5 mg once daily before breakfast because it has fewer adverse fetal effects than insulin.
Restrict her daily carbohydrate intake to less than 15% of total calories and continue MNT for another 4 weeks.
Reassure the patient that pregnancy fasting levels up to 115 mg/dL are acceptable and maintain current dietary therapy.
A 30-year-old P1 presents for her comprehensive 6-week postpartum visit following an uncomplicated spontaneous vaginal delivery at 39 weeks. Her antepartum course was notable for diet-controlled gestational diabetes mellitus (A1GDM). Her fasting and postprandial blood glucose checks in the immediate postpartum period were normal, and she is currently asymptomatic and exclusively breastfeeding. What is the recommended diabetes screening protocol for this patient at this time?
No further testing is necessary because diet-controlled gestational diabetes completely resolves following placental delivery.
Order a random urine dipstick for glycosuria today and re-evaluate only if she becomes symptomatic.
Check a serum hemoglobin A1c today and discharge her from diabetes surveillance if it is less than 6.5%.
Administer a fasting 75-g 2-hour oral glucose tolerance test (OGTT) to screen for prediabetes and overt type 2 diabetes mellitus.
Sections you finish are checked off in the contents.